BROADWOOD CAPITAL INC - Q2 2021 holdings

$2.24 Billion is the total value of BROADWOOD CAPITAL INC's 7 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 12.5% .

 Value Shares↓ Weighting
STAA SellSTAAR SURGICAL CO$1,321,296,000
+31.3%
8,664,239
-9.2%
59.06%
+10.4%
MNST  MONSTER BEVERAGE CORP NEW$425,370,000
+0.3%
4,656,4880.0%19.01%
-15.7%
IWM  ISHARES TRrussell 2000 etf$158,265,000
+3.8%
690,0000.0%7.07%
-12.7%
AXON  AXON ENTERPRISE INC$134,379,000
+24.1%
760,0620.0%6.01%
+4.4%
LCTX  LINEAGE CELL THERAPEUTICS IN$96,915,000
+21.3%
34,005,3790.0%4.33%
+2.0%
OCX  ONCOCYTE CORP$96,297,000
+10.6%
16,776,4840.0%4.30%
-7.0%
AGE  AGEX THERAPEUTICS INC$4,646,000
-4.3%
2,997,1560.0%0.21%
-19.4%
MNST ExitMONSTER BEVERAGE CORP NEWput$0-200,000
-100.0%
-0.97%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-08-16
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
STAAR SURGICAL CO42Q3 202359.1%
MONSTER BEVERAGE CORP NEW34Q3 202349.7%
ISHARES TR33Q3 202314.8%
ONCOCYTE CORPORATION31Q2 20234.6%
BIOTIME INC25Q2 201917.8%
AXON ENTERPRISE INC24Q3 202313.4%
AGEX THERAPEUTICS INC20Q3 20231.5%
LINEAGE CELL THERAPEUTICS INC17Q3 20235.1%
ASTERIAS BIOTHERAPEUTICS INC16Q4 20182.9%
CYNOSURE INC15Q4 201610.4%

View BROADWOOD CAPITAL INC's complete holdings history.

Latest filings
TypeFiled
42024-04-15
13F-HR2024-02-14
42024-02-08
42024-01-10
42024-01-05
42023-11-30
13F-HR2023-11-14
42023-11-14
42023-11-09
42023-11-06

View BROADWOOD CAPITAL INC's complete filings history.

Compare quarters

Export BROADWOOD CAPITAL INC's holdings